Outcomes Related to Antiplatelet or Anticoagulation Use in Patients Undergoing Carotid Endarterectomy

Background The number of cases involving patients undergoing vascular procedures who are prescribed clopidogrel or warfarin as treatment options continues to rise. Our aim was to examine outcomes related to antiplatelet or anticoagulation therapy in patients undergoing carotid endarterectomy (CEA)....

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Annals of vascular surgery 2011, Vol.25 (1), p.25-31
Hauptverfasser: Rosenbaum, Andrew, Rizvi, Adnan Z, Alden, Peter B, Tretinyak, Alexander S, Graber, John N, Goldman, Jo Anne, Sullivan, Timothy M
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 31
container_issue 1
container_start_page 25
container_title Annals of vascular surgery
container_volume 25
creator Rosenbaum, Andrew
Rizvi, Adnan Z
Alden, Peter B
Tretinyak, Alexander S
Graber, John N
Goldman, Jo Anne
Sullivan, Timothy M
description Background The number of cases involving patients undergoing vascular procedures who are prescribed clopidogrel or warfarin as treatment options continues to rise. Our aim was to examine outcomes related to antiplatelet or anticoagulation therapy in patients undergoing carotid endarterectomy (CEA). Methods A retrospective review of 260 consecutive patients undergoing CEA. Data including patient demographics, operative details, perioperative use of aspirin (ASA), clopidogrel, or warfarin, and early and/or late outcome(s) were collected. Endpoints included postoperative morbidity and/or mortality rate(s) and bleeding complications. Results The study included 152 men and 108 women (mean age = 69.3 years), with a mean follow-up of 406 days. In all, 46% of endarterectomies were for a symptomatic disease. The technique of eversion endarterectomy was applied in 126 (48.5%), Dacron-patch in 112 (43.1%), and bovine pericardial-patch in 14 (5.4%) of the cases. Among the patients, 171 were taking ASA, 50 were taking clopidogrel ± ASA, and 10 were taking warfarin (mean INR = 1.62; range, 1.2-2.1); the remaining 29 were not on any antiplatelet therapy. All patients who were on warfarin therapy underwent an eversion endarterectomy. Overall, there were 19 (7.3%) complications (12 major and seven minor). The 30-day stroke rate and stroke death rate was 0.7% and 1.1%, respectively. Patients taking clopidogrel developed more number of neck hematomas (16% vs. 1.7%, p = 0.0004) compared with patients who were on ASA alone. For patients taking clopidogrel, Dacron-patch repair resulted in more hematomas than eversion endarterectomy (35% vs. 4.2%, p = 0.012). There was no difference in the incidence of neck hematoma on the basis of endarterectomy technique in patients who were on ASA alone. The patients taking warfarin neither had a perioperative complication nor developed a neck hematoma. Conclusions In this study, clopidogrel use during CEA resulted in a significant risk for developing a neck hematoma, particularly when using a Dacron-patch. The risk of a neck hematoma in patients who were on clopidogrel was much less when an eversion endarterectomy was performed.
doi_str_mv 10.1016/j.avsg.2010.06.007
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_820791547</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0890509610003018</els_id><sourcerecordid>820791547</sourcerecordid><originalsourceid>FETCH-LOGICAL-c410t-b221240c60d79d7eaaed1907adc22784332fb7e71ab7fdea6097a858c7acd3fe3</originalsourceid><addsrcrecordid>eNp9kU-LFDEQxYMo7uzqF_AguXnqsZL-kzSIsAy7rrCwos45ZJLqIWN3Mibphfn2pp3VgwdPxSvee1C_IuQNgzUD1r0_rPVj2q85lAV0awDxjKxYx9qq7RvxnKxA9lC10HcX5DKlAwDjspEvyQUHKXvesxXBhzmbMGGiX3HUGS3NgV777I6LGjHTEH9rE_R-LjsXPN0mpM7TL0Whz4luvcW4D87v6UbHkJ2lN97qmDGiyWE6vSIvBj0mfP00r8j29ub75q66f_j0eXN9X5mGQa52nDPegOnAit4K1Bot60FoazgXsqlrPuwECqZ3YrCoO-iFlq00QhtbD1hfkXfn3mMMP2dMWU0uGRxH7THMSUkOomdtI4qTn50mhpQiDuoY3aTjSTFQC111UAtdtdBV0KlCt4TePtXPuwnt38gfnMXw4WzAcuSjw6iSKYgMWreQUDa4__d__CduRued0eMPPGE6hDn6gk8xlbgC9W357_JeBgA1MFn_AiJZoj0</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>820791547</pqid></control><display><type>article</type><title>Outcomes Related to Antiplatelet or Anticoagulation Use in Patients Undergoing Carotid Endarterectomy</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>Rosenbaum, Andrew ; Rizvi, Adnan Z ; Alden, Peter B ; Tretinyak, Alexander S ; Graber, John N ; Goldman, Jo Anne ; Sullivan, Timothy M</creator><creatorcontrib>Rosenbaum, Andrew ; Rizvi, Adnan Z ; Alden, Peter B ; Tretinyak, Alexander S ; Graber, John N ; Goldman, Jo Anne ; Sullivan, Timothy M</creatorcontrib><description>Background The number of cases involving patients undergoing vascular procedures who are prescribed clopidogrel or warfarin as treatment options continues to rise. Our aim was to examine outcomes related to antiplatelet or anticoagulation therapy in patients undergoing carotid endarterectomy (CEA). Methods A retrospective review of 260 consecutive patients undergoing CEA. Data including patient demographics, operative details, perioperative use of aspirin (ASA), clopidogrel, or warfarin, and early and/or late outcome(s) were collected. Endpoints included postoperative morbidity and/or mortality rate(s) and bleeding complications. Results The study included 152 men and 108 women (mean age = 69.3 years), with a mean follow-up of 406 days. In all, 46% of endarterectomies were for a symptomatic disease. The technique of eversion endarterectomy was applied in 126 (48.5%), Dacron-patch in 112 (43.1%), and bovine pericardial-patch in 14 (5.4%) of the cases. Among the patients, 171 were taking ASA, 50 were taking clopidogrel ± ASA, and 10 were taking warfarin (mean INR = 1.62; range, 1.2-2.1); the remaining 29 were not on any antiplatelet therapy. All patients who were on warfarin therapy underwent an eversion endarterectomy. Overall, there were 19 (7.3%) complications (12 major and seven minor). The 30-day stroke rate and stroke death rate was 0.7% and 1.1%, respectively. Patients taking clopidogrel developed more number of neck hematomas (16% vs. 1.7%, p = 0.0004) compared with patients who were on ASA alone. For patients taking clopidogrel, Dacron-patch repair resulted in more hematomas than eversion endarterectomy (35% vs. 4.2%, p = 0.012). There was no difference in the incidence of neck hematoma on the basis of endarterectomy technique in patients who were on ASA alone. The patients taking warfarin neither had a perioperative complication nor developed a neck hematoma. Conclusions In this study, clopidogrel use during CEA resulted in a significant risk for developing a neck hematoma, particularly when using a Dacron-patch. The risk of a neck hematoma in patients who were on clopidogrel was much less when an eversion endarterectomy was performed.</description><identifier>ISSN: 0890-5096</identifier><identifier>EISSN: 1615-5947</identifier><identifier>DOI: 10.1016/j.avsg.2010.06.007</identifier><identifier>PMID: 20889291</identifier><language>eng</language><publisher>Netherlands: Elsevier Inc</publisher><subject>Adult ; Aged ; Aged, 80 and over ; Anticoagulants - adverse effects ; Anticoagulants - therapeutic use ; Aspirin - therapeutic use ; Chi-Square Distribution ; Endarterectomy, Carotid - adverse effects ; Endarterectomy, Carotid - mortality ; Female ; Hematoma - etiology ; Humans ; Male ; Middle Aged ; Minnesota ; Myocardial Infarction - etiology ; Platelet Aggregation Inhibitors - adverse effects ; Platelet Aggregation Inhibitors - therapeutic use ; Postoperative Hemorrhage - etiology ; Retrospective Studies ; Risk Assessment ; Risk Factors ; Stroke - etiology ; Surgery ; Ticlopidine - analogs &amp; derivatives ; Ticlopidine - therapeutic use ; Time Factors ; Treatment Outcome ; Warfarin - therapeutic use</subject><ispartof>Annals of vascular surgery, 2011, Vol.25 (1), p.25-31</ispartof><rights>Annals of Vascular Surgery Inc.</rights><rights>2011 Annals of Vascular Surgery Inc.</rights><rights>Copyright © 2011 Annals of Vascular Surgery Inc. Published by Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c410t-b221240c60d79d7eaaed1907adc22784332fb7e71ab7fdea6097a858c7acd3fe3</citedby><cites>FETCH-LOGICAL-c410t-b221240c60d79d7eaaed1907adc22784332fb7e71ab7fdea6097a858c7acd3fe3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.avsg.2010.06.007$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>315,782,786,3554,4028,27932,27933,27934,46004</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/20889291$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Rosenbaum, Andrew</creatorcontrib><creatorcontrib>Rizvi, Adnan Z</creatorcontrib><creatorcontrib>Alden, Peter B</creatorcontrib><creatorcontrib>Tretinyak, Alexander S</creatorcontrib><creatorcontrib>Graber, John N</creatorcontrib><creatorcontrib>Goldman, Jo Anne</creatorcontrib><creatorcontrib>Sullivan, Timothy M</creatorcontrib><title>Outcomes Related to Antiplatelet or Anticoagulation Use in Patients Undergoing Carotid Endarterectomy</title><title>Annals of vascular surgery</title><addtitle>Ann Vasc Surg</addtitle><description>Background The number of cases involving patients undergoing vascular procedures who are prescribed clopidogrel or warfarin as treatment options continues to rise. Our aim was to examine outcomes related to antiplatelet or anticoagulation therapy in patients undergoing carotid endarterectomy (CEA). Methods A retrospective review of 260 consecutive patients undergoing CEA. Data including patient demographics, operative details, perioperative use of aspirin (ASA), clopidogrel, or warfarin, and early and/or late outcome(s) were collected. Endpoints included postoperative morbidity and/or mortality rate(s) and bleeding complications. Results The study included 152 men and 108 women (mean age = 69.3 years), with a mean follow-up of 406 days. In all, 46% of endarterectomies were for a symptomatic disease. The technique of eversion endarterectomy was applied in 126 (48.5%), Dacron-patch in 112 (43.1%), and bovine pericardial-patch in 14 (5.4%) of the cases. Among the patients, 171 were taking ASA, 50 were taking clopidogrel ± ASA, and 10 were taking warfarin (mean INR = 1.62; range, 1.2-2.1); the remaining 29 were not on any antiplatelet therapy. All patients who were on warfarin therapy underwent an eversion endarterectomy. Overall, there were 19 (7.3%) complications (12 major and seven minor). The 30-day stroke rate and stroke death rate was 0.7% and 1.1%, respectively. Patients taking clopidogrel developed more number of neck hematomas (16% vs. 1.7%, p = 0.0004) compared with patients who were on ASA alone. For patients taking clopidogrel, Dacron-patch repair resulted in more hematomas than eversion endarterectomy (35% vs. 4.2%, p = 0.012). There was no difference in the incidence of neck hematoma on the basis of endarterectomy technique in patients who were on ASA alone. The patients taking warfarin neither had a perioperative complication nor developed a neck hematoma. Conclusions In this study, clopidogrel use during CEA resulted in a significant risk for developing a neck hematoma, particularly when using a Dacron-patch. The risk of a neck hematoma in patients who were on clopidogrel was much less when an eversion endarterectomy was performed.</description><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Anticoagulants - adverse effects</subject><subject>Anticoagulants - therapeutic use</subject><subject>Aspirin - therapeutic use</subject><subject>Chi-Square Distribution</subject><subject>Endarterectomy, Carotid - adverse effects</subject><subject>Endarterectomy, Carotid - mortality</subject><subject>Female</subject><subject>Hematoma - etiology</subject><subject>Humans</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Minnesota</subject><subject>Myocardial Infarction - etiology</subject><subject>Platelet Aggregation Inhibitors - adverse effects</subject><subject>Platelet Aggregation Inhibitors - therapeutic use</subject><subject>Postoperative Hemorrhage - etiology</subject><subject>Retrospective Studies</subject><subject>Risk Assessment</subject><subject>Risk Factors</subject><subject>Stroke - etiology</subject><subject>Surgery</subject><subject>Ticlopidine - analogs &amp; derivatives</subject><subject>Ticlopidine - therapeutic use</subject><subject>Time Factors</subject><subject>Treatment Outcome</subject><subject>Warfarin - therapeutic use</subject><issn>0890-5096</issn><issn>1615-5947</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kU-LFDEQxYMo7uzqF_AguXnqsZL-kzSIsAy7rrCwos45ZJLqIWN3Mibphfn2pp3VgwdPxSvee1C_IuQNgzUD1r0_rPVj2q85lAV0awDxjKxYx9qq7RvxnKxA9lC10HcX5DKlAwDjspEvyQUHKXvesxXBhzmbMGGiX3HUGS3NgV777I6LGjHTEH9rE_R-LjsXPN0mpM7TL0Whz4luvcW4D87v6UbHkJ2lN97qmDGiyWE6vSIvBj0mfP00r8j29ub75q66f_j0eXN9X5mGQa52nDPegOnAit4K1Bot60FoazgXsqlrPuwECqZ3YrCoO-iFlq00QhtbD1hfkXfn3mMMP2dMWU0uGRxH7THMSUkOomdtI4qTn50mhpQiDuoY3aTjSTFQC111UAtdtdBV0KlCt4TePtXPuwnt38gfnMXw4WzAcuSjw6iSKYgMWreQUDa4__d__CduRued0eMPPGE6hDn6gk8xlbgC9W357_JeBgA1MFn_AiJZoj0</recordid><startdate>2011</startdate><enddate>2011</enddate><creator>Rosenbaum, Andrew</creator><creator>Rizvi, Adnan Z</creator><creator>Alden, Peter B</creator><creator>Tretinyak, Alexander S</creator><creator>Graber, John N</creator><creator>Goldman, Jo Anne</creator><creator>Sullivan, Timothy M</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>2011</creationdate><title>Outcomes Related to Antiplatelet or Anticoagulation Use in Patients Undergoing Carotid Endarterectomy</title><author>Rosenbaum, Andrew ; Rizvi, Adnan Z ; Alden, Peter B ; Tretinyak, Alexander S ; Graber, John N ; Goldman, Jo Anne ; Sullivan, Timothy M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c410t-b221240c60d79d7eaaed1907adc22784332fb7e71ab7fdea6097a858c7acd3fe3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Anticoagulants - adverse effects</topic><topic>Anticoagulants - therapeutic use</topic><topic>Aspirin - therapeutic use</topic><topic>Chi-Square Distribution</topic><topic>Endarterectomy, Carotid - adverse effects</topic><topic>Endarterectomy, Carotid - mortality</topic><topic>Female</topic><topic>Hematoma - etiology</topic><topic>Humans</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Minnesota</topic><topic>Myocardial Infarction - etiology</topic><topic>Platelet Aggregation Inhibitors - adverse effects</topic><topic>Platelet Aggregation Inhibitors - therapeutic use</topic><topic>Postoperative Hemorrhage - etiology</topic><topic>Retrospective Studies</topic><topic>Risk Assessment</topic><topic>Risk Factors</topic><topic>Stroke - etiology</topic><topic>Surgery</topic><topic>Ticlopidine - analogs &amp; derivatives</topic><topic>Ticlopidine - therapeutic use</topic><topic>Time Factors</topic><topic>Treatment Outcome</topic><topic>Warfarin - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Rosenbaum, Andrew</creatorcontrib><creatorcontrib>Rizvi, Adnan Z</creatorcontrib><creatorcontrib>Alden, Peter B</creatorcontrib><creatorcontrib>Tretinyak, Alexander S</creatorcontrib><creatorcontrib>Graber, John N</creatorcontrib><creatorcontrib>Goldman, Jo Anne</creatorcontrib><creatorcontrib>Sullivan, Timothy M</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Annals of vascular surgery</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Rosenbaum, Andrew</au><au>Rizvi, Adnan Z</au><au>Alden, Peter B</au><au>Tretinyak, Alexander S</au><au>Graber, John N</au><au>Goldman, Jo Anne</au><au>Sullivan, Timothy M</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Outcomes Related to Antiplatelet or Anticoagulation Use in Patients Undergoing Carotid Endarterectomy</atitle><jtitle>Annals of vascular surgery</jtitle><addtitle>Ann Vasc Surg</addtitle><date>2011</date><risdate>2011</risdate><volume>25</volume><issue>1</issue><spage>25</spage><epage>31</epage><pages>25-31</pages><issn>0890-5096</issn><eissn>1615-5947</eissn><abstract>Background The number of cases involving patients undergoing vascular procedures who are prescribed clopidogrel or warfarin as treatment options continues to rise. Our aim was to examine outcomes related to antiplatelet or anticoagulation therapy in patients undergoing carotid endarterectomy (CEA). Methods A retrospective review of 260 consecutive patients undergoing CEA. Data including patient demographics, operative details, perioperative use of aspirin (ASA), clopidogrel, or warfarin, and early and/or late outcome(s) were collected. Endpoints included postoperative morbidity and/or mortality rate(s) and bleeding complications. Results The study included 152 men and 108 women (mean age = 69.3 years), with a mean follow-up of 406 days. In all, 46% of endarterectomies were for a symptomatic disease. The technique of eversion endarterectomy was applied in 126 (48.5%), Dacron-patch in 112 (43.1%), and bovine pericardial-patch in 14 (5.4%) of the cases. Among the patients, 171 were taking ASA, 50 were taking clopidogrel ± ASA, and 10 were taking warfarin (mean INR = 1.62; range, 1.2-2.1); the remaining 29 were not on any antiplatelet therapy. All patients who were on warfarin therapy underwent an eversion endarterectomy. Overall, there were 19 (7.3%) complications (12 major and seven minor). The 30-day stroke rate and stroke death rate was 0.7% and 1.1%, respectively. Patients taking clopidogrel developed more number of neck hematomas (16% vs. 1.7%, p = 0.0004) compared with patients who were on ASA alone. For patients taking clopidogrel, Dacron-patch repair resulted in more hematomas than eversion endarterectomy (35% vs. 4.2%, p = 0.012). There was no difference in the incidence of neck hematoma on the basis of endarterectomy technique in patients who were on ASA alone. The patients taking warfarin neither had a perioperative complication nor developed a neck hematoma. Conclusions In this study, clopidogrel use during CEA resulted in a significant risk for developing a neck hematoma, particularly when using a Dacron-patch. The risk of a neck hematoma in patients who were on clopidogrel was much less when an eversion endarterectomy was performed.</abstract><cop>Netherlands</cop><pub>Elsevier Inc</pub><pmid>20889291</pmid><doi>10.1016/j.avsg.2010.06.007</doi><tpages>7</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0890-5096
ispartof Annals of vascular surgery, 2011, Vol.25 (1), p.25-31
issn 0890-5096
1615-5947
language eng
recordid cdi_proquest_miscellaneous_820791547
source MEDLINE; Elsevier ScienceDirect Journals Complete
subjects Adult
Aged
Aged, 80 and over
Anticoagulants - adverse effects
Anticoagulants - therapeutic use
Aspirin - therapeutic use
Chi-Square Distribution
Endarterectomy, Carotid - adverse effects
Endarterectomy, Carotid - mortality
Female
Hematoma - etiology
Humans
Male
Middle Aged
Minnesota
Myocardial Infarction - etiology
Platelet Aggregation Inhibitors - adverse effects
Platelet Aggregation Inhibitors - therapeutic use
Postoperative Hemorrhage - etiology
Retrospective Studies
Risk Assessment
Risk Factors
Stroke - etiology
Surgery
Ticlopidine - analogs & derivatives
Ticlopidine - therapeutic use
Time Factors
Treatment Outcome
Warfarin - therapeutic use
title Outcomes Related to Antiplatelet or Anticoagulation Use in Patients Undergoing Carotid Endarterectomy
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-02T07%3A59%3A33IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Outcomes%20Related%20to%20Antiplatelet%20or%20Anticoagulation%20Use%20in%20Patients%20Undergoing%20Carotid%20Endarterectomy&rft.jtitle=Annals%20of%20vascular%20surgery&rft.au=Rosenbaum,%20Andrew&rft.date=2011&rft.volume=25&rft.issue=1&rft.spage=25&rft.epage=31&rft.pages=25-31&rft.issn=0890-5096&rft.eissn=1615-5947&rft_id=info:doi/10.1016/j.avsg.2010.06.007&rft_dat=%3Cproquest_cross%3E820791547%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=820791547&rft_id=info:pmid/20889291&rft_els_id=S0890509610003018&rfr_iscdi=true